Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies - Sorbonne Université
Journal Articles The Lancet Year : 2018

Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies

No file

Dates and versions

hal-03777527 , version 1 (14-09-2022)

Identifiers

Cite

Martin Gartland, Michael Aboud, Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.. Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies. The Lancet, 2018, 391 (10123), pp.839--849. ⟨10.1016/S0140-6736(17)33095-7⟩. ⟨hal-03777527⟩
18 View
0 Download

Altmetric

Share

More